You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

AMPHETAMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Amphetamine, and what generic alternatives are available?

Amphetamine is a drug marketed by Actavis Labs Fl Inc, Alkem Labs Ltd, Amneal Pharms, Aurolife Pharma Llc, Bionpharma, Dr Reddys Labs Sa, Epic Pharma Llc, Glenmark Pharms Ltd, Granules, Lannett, Novast Labs, Prinston Inc, Rhodes Pharms, Sanaluz, Senores Pharms, Specgx Llc, and Sun Pharm Inds Inc. and is included in seventeen NDAs.

The generic ingredient in AMPHETAMINE is amphetamine sulfate. There are fifty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the amphetamine sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Amphetamine

A generic version of AMPHETAMINE was approved as amphetamine sulfate by AMNEAL PHARMS on September 26th, 2018.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AMPHETAMINE?
  • What are the global sales for AMPHETAMINE?
  • What is Average Wholesale Price for AMPHETAMINE?
Drug patent expirations by year for AMPHETAMINE
Drug Prices for AMPHETAMINE

See drug prices for AMPHETAMINE

Drug Sales Revenue Trends for AMPHETAMINE

See drug sales revenues for AMPHETAMINE

Recent Clinical Trials for AMPHETAMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of ZurichPhase 1
Stephen Robert MarderPhase 2
Virginia Commonwealth UniversityPhase 2

See all AMPHETAMINE clinical trials

Paragraph IV (Patent) Challenges for AMPHETAMINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ADZENYS XR-ODT Extended-release Orally Disintegrating Tablets amphetamine 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg 204326 1 2016-05-10

US Patents and Regulatory Information for AMPHETAMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanaluz AMPHETAMINE SULFATE amphetamine sulfate TABLET;ORAL 212582-002 Feb 4, 2020 AA RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Prinston Inc AMPHETAMINE SULFATE amphetamine sulfate TABLET;ORAL 211861-002 Mar 11, 2020 AA RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Senores Pharms AMPHETAMINE SULFATE amphetamine sulfate TABLET;ORAL 212901-001 May 22, 2020 AA RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Rhodes Pharms AMPHETAMINE SULFATE amphetamine sulfate TABLET;ORAL 213852-001 Sep 7, 2021 AA RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Actavis Labs Fl Inc AMPHETAMINE amphetamine TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 209253-001 Jun 22, 2023 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Epic Pharma Llc AMPHETAMINE SULFATE amphetamine sulfate TABLET;ORAL 213980-002 Oct 27, 2020 AA RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

AMPHETAMINE Market Analysis and Financial Projection Experimental

Amphetamine Drug Market: Dynamics and Financial Trajectory

Introduction

The amphetamine drug market is poised for significant growth, driven by a combination of factors including increasing prevalence of central nervous system disorders, government support, and advancements in drug development. Here, we delve into the market dynamics, growth drivers, challenges, and the financial trajectory of the amphetamine drug market.

Market Size and Growth Projections

The amphetamine drug market is expected to witness a lucrative growth rate between 2024 and 2036. This growth is attributed to the rising number of people suffering from various disorders such as Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, obesity, and depression[1][4].

Growth Drivers

Increased Prevalence of Disorders

The surge in central nervous system disorders, sleeping disorders, and depression cases is a significant driver of the market. The global increase in the prevalence of depression among adults and children is particularly noteworthy, with the depression segment anticipated to dominate the market[1].

Government Support and Approvals

Government approvals and the commercialization of new drugs by market players are crucial factors driving market growth. Governments around the world are supporting the ADHD drug market to address the growing number of patients with these conditions[1].

Research and Development

Increased research and development activities, along with the simultaneous approval of new drugs, are also driving the market forward. Collaborations among key market players to enhance product development and commercialization further boost market growth[1][4].

Market Segmentation

By Application

The amphetamine drug market is segmented into ADHD, narcolepsy, obesity, depression, and other applications. The depression segment is expected to dominate due to the increasing prevalence of depression globally[1].

By Demographics

The market is bifurcated into children and adults, with the adult segment anticipated to hold the largest share. This is due to the larger adult patient population[1].

By Distribution Channel

The market is also segmented by distribution channels, including retail pharmacies, hospitals, and online platforms. Retail pharmacies are expected to play a significant role in the distribution of amphetamine drugs[4].

By Region

The global amphetamine drug market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is predicted to dominate the majority of the revenue share by 2036, followed by Europe and the Asia Pacific region[1][4].

Regional Analysis

North America

North America is expected to dominate the market due to the high prevalence of depression and ADHD patients. Collaborations among market players and efforts to increase market penetration for product development and commercialization are key factors contributing to this dominance[1].

Europe

Europe is anticipated to hold the second-largest market share, driven by the presence of major pharmaceutical companies and increasing awareness about mental health in the region[1].

Asia Pacific

The Asia Pacific region is expected to expand at a higher rate during the forecast period due to the increasing demand for drugs to treat various disorders such as ADHD[1].

Challenges

Regulatory Hurdles

Strict regulations and the illegal use of amphetamine drugs pose significant challenges to the market. For instance, seizures of amphetamine and methamphetamine have skyrocketed, indicating stringent control measures[1][3].

Social and Environmental Factors

Individual, social, and environmental factors influence the use trajectory of amphetamine-type stimulants. These include reasons for initiation, continuation, increase, and decrease in use, such as managing stress, social belonging, and financial instability[2].

Financial Trajectory

Revenue Growth

The market is projected to see substantial revenue growth driven by the increasing demand for amphetamine drugs. The CAGR for the retail pharmacy segment, for example, is expected to be significant during the forecast period[4].

Market Share

Key players in the market are expected to maintain and expand their market share through strategic collaborations, research and development, and effective commercialization strategies[1][4].

Impact of Illegal Use

Global Control Measures

The illegal use of amphetamine drugs is being strictly controlled globally. Seizures of amphetamine pills have been reported in various regions, highlighting the efforts to curb illegal trafficking[1][3].

Consumer Behavior and Health Impacts

Addiction and Health Risks

The use of amphetamine drugs, especially for non-medical purposes, can lead to addiction and severe health risks. Users often experience increased tolerance, withdrawal effects, and negative health impacts, which can affect their long-term well-being[2][3].

Case Studies

Personal accounts, such as the one from a finance professional who experienced career downfall due to Adderall use, highlight the potential professional and personal risks associated with dependency on these drugs[5].

Key Takeaways

  • The amphetamine drug market is expected to grow significantly between 2024 and 2036.
  • The market is driven by the increasing prevalence of central nervous system disorders, government support, and advancements in drug development.
  • North America is predicted to dominate the market, followed by Europe and the Asia Pacific region.
  • Strict regulations and the illegal use of amphetamine drugs pose challenges to the market.
  • Individual, social, and environmental factors significantly influence the use trajectory of amphetamine-type stimulants.

FAQs

Q: What are the primary drivers of the amphetamine drug market? A: The primary drivers include the increasing prevalence of central nervous system disorders, government support, and advancements in drug development.

Q: Which region is expected to dominate the amphetamine drug market? A: North America is expected to dominate the majority of the revenue share by 2036.

Q: What are the challenges faced by the amphetamine drug market? A: The market faces challenges such as strict regulations, illegal use of amphetamine drugs, and the influence of individual, social, and environmental factors on drug use trajectories.

Q: How does the illegal use of amphetamine drugs impact the market? A: The illegal use of amphetamine drugs is being strictly controlled globally, with significant seizures reported, which can affect market dynamics and consumer behavior.

Q: What are the potential health risks associated with amphetamine drug use? A: The use of amphetamine drugs can lead to addiction, increased tolerance, withdrawal effects, and negative health impacts, affecting long-term well-being.

Sources

  1. Research Nester, "Amphetamine Drug Market Size & Share, Growth Analysis 2036".
  2. PubMed, "Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory?"
  3. UNODC, "DRUG MARKET TRENDS 2022".
  4. Cognitive Market Research, "Amphetamine Drug Market Report 2024 (Global Edition)".
  5. Wall Street Oasis, "How Adderall ruined my career in finance".

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.